Nivolumab is a human IgG4 anti-PD-1 monoclonal antibody that has been studied as a single agent (NCT02275533) and in combination with chemotherapy (NCT02397720, NCT02464657) in adults with newly diagnosed and relapsed/refractory (R/R) AML [11,12,13,14]. This evidence concerns the gene PDCD1 and acute myeloid leukemia.